Briacell Therap (BCTX) Competitors

Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, indicating that its share price is 222% more volatile than the broader market.

Black Diamond Therapeutics' return on equity of -30.18% beat Briacell Therap's return on equity.

In the previous week, Briacell Therap's average media sentiment score of 0.98 beat Black Diamond Therapeutics' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Black Diamond Therapeutics has higher revenue and earnings than Briacell Therap. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Black Diamond Therapeutics has a consensus price target of $10.00, indicating a potential upside of 437.63%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Briacell Therap.

Promis Neurosciences currently has a consensus target price of $26.50, suggesting a potential upside of 158.79%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap.

In the previous week, Promis Neurosciences had 3 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for Promis Neurosciences and 0 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.98 beat Promis Neurosciences' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the news media.

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Briacell Therap's return on equity of -153.53% beat Promis Neurosciences' return on equity.

Promis Neurosciences has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

Briacell Therap has higher earnings, but lower revenue than ALT5 Sigma.

In the previous week, Briacell Therap's average media sentiment score of 0.98 beat ALT5 Sigma's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Briacell Therap has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Briacell Therap's return on equity.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Anixa Biosciences has higher revenue and earnings than Briacell Therap. Anixa Biosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 210.22%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than Briacell Therap.

Anixa Biosciences' return on equity of -71.12% beat Briacell Therap's return on equity.

In the previous week, Anixa Biosciences had 1 more articles in the media than Briacell Therap. MarketBeat recorded 1 mentions for Anixa Biosciences and 0 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.98 beat Anixa Biosciences' score of 0.88 indicating that Briacell Therap is being referred to more favorably in the news media.

Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.